A novel fluorescent nanobeacon can distinguish normal from diseased colon tissue, potentially offering advantages for colorectal cancer screening.

Several investigators in Vanderbilt-Ingram Cancer Center’s (VICC) Breast Cancer Program have received grant awards to support translational research that may improve disease outcomes for patients.

Despite dramatic recent advances in treatment, colorectal cancer killed more than 49,000 Americans last year, according to the National Cancer Institute, making it the second most lethal malignancy after cancers of the lung and bronchus.

Faced with the negative quality-of-life effects from surgery and radiation treatments for prostate cancer, low risk patients may instead want to consider active surveillance with their physician, according to a study released Tuesday by the Journal of the American Medical Association (JAMA).

Vanderbilt investigators have discovered that activated epidermal growth factor receptor may be a target for therapies to prevent colorectal cancer development.

With the help of a drug formerly used to treat HIV/AIDS, researchers at Vanderbilt University Medical Center (VUMC) have found a way to make melanoma cells more vulnerable to targeted anti-cancer therapy.

Michelle Alvarez, center, served as patient ambassador for Monroe Carell Jr. Children’s Hospital at Vanderbilt at the recent Nashville Predators Hockey Fights Cancer Night.